Table 1.
Clinical characteristics in relation to the 18F-FDG uptake of visceral adipose tissue.
| SUV-High, n = 73 (%) | SUV-Low, n = 75 (%) | p value | |
|---|---|---|---|
| Age (year, mean ± SD) | 50.90 ± 11.22 | 49.08 ± 8.30 | 0.264 |
| BMI (mean ± SD) | 23.19 ± 3.49 | 23.50 ± 3.11 | 0.571 |
| SUVmax-tumor | 4.50 ± 3.28 | 4.47 ± 4.04 | 0.960 |
| Serum glucose (mg/dL, mean ± SD) | 99.80 ± 14.18 | 103.24 ± 20.80 | 0.257 |
| DM | 0.513 | ||
| No | 71 (97.3) | 72 (96.0) | |
| Yes | 2 (2.7) | 3 (4.0) | |
| ER | 0.211 | ||
| Positive | 47 (64.4) | 41 (54.7) | |
| Negative | 23 (31.5) | 31 (41.3) | |
| Missing | 3 (4.1) | 3 (4) | |
| PR | 0.721 | ||
| Positive | 40 (54.8) | 39 (52) | |
| Negative | 30 (41.1) | 33 (44) | |
| Missing | 3 (4.1) | 3 (4) | |
| HER2 | 0.657 | ||
| Positive | 17 (23.3) | 21 (28) | |
| Negative | 48 (65.8) | 50 (66.7) | |
| Missing | 8 (11.0) | 4 (5.3) | |
| HG | 0.942 | ||
| I, II | 39 (53.4) | 38 (50.7) | |
| III | 26 (35.6) | 26 (34.7) | |
| Missing | 8 (11.0) | 11 (14.7) | |
| Tumor size | 0.168 | ||
| ≤ 2 cm | 48 (65.8) | 41 (54.7) | |
| > 2 cm | 25 (34.2) | 34 (45.3) | |
| Lymph node metastasis | 0.414 | ||
| Negative | 47 (64.4) | 53 (70.7) | |
| Positive | 26 (35.6) | 22 (29.3) | |
| AJCC stage* | 0.943 | ||
| I | 35 (47.9) | 36 (48) | |
| II | 30 (41.1) | 32 (42.7) | |
| III | 8 (11.0) | 7 (9.3) | |
| Lymphovascular invasion | 0.628 | ||
| Negative | 12 (16.4) | 14 (18.7) | |
| Positive | 52 (71.2) | 49 (65.3) | |
| Missing | 9 (12.3) | 12 (16) | |
| Chemotherapy | 0.765 | ||
| Done | 45 (61.6) | 48 (64) | |
| Not done | 25 (34.2) | 24 (32) | |
| Missing | 3 (4.1) | 3 (4) | |
| Radiotherapy | 0.203 | ||
| Done | 33 (45.2) | 24 (32) | |
| Not done | 37 (50.7) | 42 (56) | |
| Missing | 3 (4.1) | 9 (12) | |
| Endocrine therapy | 0.446 | ||
| Done | 49 (67.1) | 44 (58.7) | |
| Not done | 23 (31.5) | 27 (36) | |
| Missing | 1 (1.4) | 4 (5.3) |
SD Standard deviation; BMI Body mass index; DM Diabetes mellitus; ER Estrogen receptor; PR Progesterone receptor; HER2, Human epidermal growth factor receptor 2; HG Histologic grade.
*AJCC stage was performed based on 8th edition.